This is the authors' abstract. We don't add key points for this paper.
Major depressive disorder (MDD) represents a sizable economic burden in Spain. Pharmacogenetic (PGx) screening to guide the choice of antidepressant medication (ADM) in MDD patients yields higher response and remission rates, which could reduce both healthcare and indirect costs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lopez-Saavedra et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: